Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

PHASE3CompletedINTERVENTIONAL
Enrollment

473

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Allergic Rhinitis Due to Grass Pollens
Interventions
DRUG

300 IR

300 IR grass pollen allergen extract tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season

DRUG

Placebo

Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season

Trial Locations (19)

15241

Allergy & Clinical Immunology Associates, Pittsburgh

21224

Johns Hopkins University, Baltimore

37203

Vanderbilt University Medical Center, Nashville

40508

University of Kentucky Medical Center, Lexington

42301

Allergy & Asthma Specialists, PSC, Owensboro

45231

Bernstein Clinical Research Center, LLC, Cincinnati

48197

Respiratory Medical Research Institute of Michigan PLC, Ypsilanti

59101

Montana Allergy & Asthma Specialists, Billings

59808

Montana Medical Research, Missoula

61761

Sneeze, wheeze, and Itch Associates, LLC, Normal

63141

Midwest Clinical Research LLC, St Louis

64093

Clinical Research of the Ozarks, Inc, Warrensburg

65203

Clinical Research of the Ozarks, Inc., Columbia

68131

Creighton University - Allergy & Asthma, Omaha

97035

Baker Allergy, Asthma, & Dermatology Research Center, LLC, Lake Oswego

97213

Allergy Associates Research, Portland

97401

Allergy and Asthma Research Group, Eugene

97504

Clinical Research Institute of Southern Oregon, P.C., Medford

98664

North West Asthma Allergy Center, Vancouver

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Stallergenes Greer

INDUSTRY

NCT00955825 - Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis | Biotech Hunter | Biotech Hunter